Nasdaq 100 Stocks SEC Filings — July 21, 2026

Revenue grew 18.5% YoY to $2.89B, accelerating from prior quarters, driven by strong da Vinci procedure volumes and system placements

Gross margin expanded 150 bps YoY to 67.8%, indicating improved product mix and cost efficiencies, a key driver of earnings outperformance

Operating income surged 30.7% YoY to $971.9M, significantly outpacing revenue growth, demonstrating strong operating leverage and cost discipline

Net income rose 24.3% YoY to $818.1M, with diluted EPS of $2.29, up from $1.81, reflecting both operational strength and the impact of aggressive buybacks

Share repurchases exploded to $1.44B in H1 2026, up from just $181M in H1 2025, a 7x increase signaling extreme management confidence in intrinsic value

Operating expenses grew only 13.0% YoY, well below revenue growth, indicating disciplined spending and margin expansion potential

Cash and equivalents declined 18% from year-end 2025 to $2.76B, a direct result of the aggressive buyback program, which could limit financial flexibility [NEUTRAL/BEARISH]

No insider trading activity reported in the filing, a neutral signal, but the lack of insider selling during a period of record buybacks is a positive

No forward guidance provided in the 10-Q, creating uncertainty around future procedure volume growth and system sales trends

Cash reserves fell 18% from year-end 2025 to $2.76B due to $1.44B in buybacks, potentially limiting the company's ability to pursue M&A or weather a downturn

The 7x increase in buybacks to $1.44B in H1 2026 may not be sustainable if revenue growth slows, potentially leading to a future reduction in shareholder returns

While below revenue growth, operating expenses still rose 13% YoY to $988.5M, and any acceleration could compress margins

The absence of forward-looking statements in the 10-Q leaves investors without a clear catalyst calendar, increasing uncertainty around near-term performance

The filing does not report any insider transactions, which could mask potential selling by executives that would be a bearish signal

With the stock likely trading at a premium multiple given its growth and margins, any slowdown in procedure volumes could lead to a sharp de-rating

Gross margins expanded 150 bps YoY to 67.8%, and with operating leverage continuing, further margin expansion could drive earnings beats and multiple expansion

The aggressive $1.44B buyback in H1 2026 is a powerful tailwind for EPS growth, potentially driving the stock higher as the reduced share count compounds earnings

18.5% YoY revenue growth in Q2 2026 suggests strong procedure volume recovery and system adoption, with potential for acceleration as new products launch

With operating income growing 30.7% YoY vs 18.5% revenue growth, the company is demonstrating significant operating leverage, a key driver of future earnings surprises

As the dominant player in robotic surgery, Intuitive Surgical benefits from high barriers to entry and recurring revenue from instruments and accessories, providing a durable competitive advantage

The absence of insider selling during a period of record buybacks and strong performance is a positive signal, suggesting management sees further upside

Intuitive Surgical's 18.5% YoY revenue growth underscores the continued expansion of robotic-assisted surgery, driven by procedure volume growth and system placements, a key theme in the med-tech sector

The 7x increase in share buybacks to $1.44B in H1 2026 reflects a broader trend of cash-rich companies returning capital to shareholders, but also raises questions about investment in growth vs. financial engineering

Intuitive Surgical's 30.7% operating income growth outpacing 18.5% revenue growth highlights a sector-wide theme of companies leveraging scale to expand margins, a key driver of earnings beats

The 18% decline in cash reserves due to aggressive buybacks illustrates the trade-off between shareholder returns and financial flexibility, a theme that will be closely watched by investors across the NASDAQ-100

The Q2 2026 earnings call will be critical for forward guidance on procedure volumes, system sales, and the sustainability of the buyback program. Watch for any commentary on Q3 trends [Date: TBD, typically late July]

Monitor the Q3 2026 10-Q for any further decline in cash reserves. If cash falls below $2.5B, it could signal an unsustainable buyback pace [Next filing: late October 2026]

Watch for any Form 4 filings from executives in the coming weeks. Any significant insider selling after the buyback surge would be a major red flag [Ongoing]

Monitor for any new product launches or regulatory approvals from competitors like Medtronic or Johnson & Johnson that could threaten Intuitive's market share [Ongoing]

Look for any industry reports or hospital data on robotic surgery volumes for Q3 2026, which could provide leading indicators for the next earnings report [Ongoing]

Watch for any FDA approvals or recalls related to the da Vinci system, which could impact system sales and procedure volumes [Ongoing]